DailyIQ
DailyIQ
Last updatedUpdating…

CELC·Celcuity Inc.

$64.33
+0.16 (+0.25%)
After Hours
High
$64.60
Open
$64.20
Market Cap
3.16B
52W High
$156.99
Low
$61.71
P. Close
$64.33
P/E
-
52W Low
$53.54
Fwd P/E
-12874.00
DailyIQ Est.
$156.59
Inst. Own.
33.2%
Short Interest
20.87%
Days to Cover
5.8
NewEarnings release, scored · filed Nov 5, 2026tone -13.5 vs prior release · 107 lines scoredSee the breakdown
Technical Score (1D)
11
BEARISH
News Sentiment
61
BULLISH
With a Technical Score of 11, Celcuity Inc. (CELC) sits in the bottom tier of the momentum ranking on the 1D timeframe. The bearish bias and SELL signal follow from that rank, and trend strength reads as weak. Sentiment at 61 is diverging from the chart. Because the score is relative, it can stay low even in a rising market if CELC keeps trailing its peers. $61.80 is the near-term floor and $66.94 is where a recovery attempt would meet its first test. A bottom momentum rank reflects the prior year of trading, so it changes gradually even when the stock has a strong week. For near-term direction, price levels give the earlier read: a close back above $66.94 on real volume would be the first sign of repair, while a break of $61.80 keeps the bearish trend in charge.
LOW TARGET
$130 +102.0%
2 analysts
MEAN TARGET
$151 +134.3%
6 analysts
HIGH TARGET
$177 +175.0%
13 analysts
PRICE RANGE
$130.00 - $177.00
SB / B / H / S / SS
7/11/1/1/1
DAILYIQ EST.
$156.59 (+143.3%)
Bought (1Y)
0 shares
$0
Sold (1Y)
0 shares
$0
Furcht Leo-
Option Exercise250 shares2026-10-07
Furcht Leo-
Option Exercise250 shares2026-10-07
GRYSKA DAVID W-
Award/Grant893 shares2026-10-01
Hahne VickyChief Financial Officer
Award/Grant10,000 shares2026-08-14
Hahne VickyChief Financial Officer
Award/Grant16,000 shares2026-08-14
37/ 100
Bearish
Overall: Bearish
✕Negative operating cash flow
✕High liabilities relative to assets
✓Analyst target above current price
Current Ratio
10.55x
Debt / Equity
1.37x
Return on Equity
-176.1%

EPS

EstBeatMiss
$-1.56$-1.34$-1.12$-0.90$-0.68Q3'25Q3'26
QtrEstActual+/−
Q3'26$-1.46$-1.33+9.0%
Q3'25$-0.96$-0.78+18.5%

Revenue

EstBeatMiss
$-0.15$-0.075$0$0.075$0.15Q3'25Q3'26
QtrEstActual+/−
Q3'26 - $0 -
Q3'25 - $0 -

Market Data

CELC Stock Snapshot

BEARISH11/100
$64.37+$0.04 (0.1%)
Market cap
3.16B
Day range
$61.71 – $64.60
News sentiment
61/100 · Bullish
Analyst target
$150.85 (+134.3%)
Consensus
Buy · 21 analysts
52-week range+20.2% off low · -59.0% from high
$53.54$156.99
Price $64.37 DailyIQ Est. $156.59

Price action on CELC is defensive - rallies are being sold rather than extended. At this size, a single catalyst moves the stock further than it would a larger peer.

Sector Rotation

Is money rotating into or out of CELC's sector?

Celcuity Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Biotechnology industry group, CELC ranks 9th of 15 tracked industries, weakening.

Sector rank
#2 of 12
Sector state
Weakening
Sector rotation score
82
Industry rank
#9 of 15

Options Market

What is the options market pricing for CELC?

CallsPuts

For Celcuity Inc.'s nearest expiry (2026-11-20, 5 days out), open interest is roughly balanced between puts and calls (put/call ratio of 0.96), with at-the-money implied volatility around 96.2%. The options market is pricing roughly a ±10.7% move by that expiry — a range of about $57.50–$71.24.

Put/call ratio (2026-11-20)
0.96
ATM implied volatility
96.2%
Total open interest
2,617
Expected move by 2026-11-20
±10.7% ($57.50–$71.24)

Analyst Consensus Estimates

What do analysts expect CELC to earn?

Analysts expect Celcuity Inc. to earn -$4.39 per share in the fiscal year ending Dec 2026 and $6.56 in the fiscal year ending Dec 2029, from 2 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.

Quarter endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Sep 2026-$1.51-$1.60 to -$1.422$1M10
Dec 2026-$0.82-$1.13 to -$0.512$23M11
Mar 2027-$1.14-$1.26 to -$1.032--
Jun 2027-$1.04-$1.19 to -$0.892--
Sep 2027-$0.84-$0.87 to -$0.802--
Fiscal year endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026-$4.39-$4.48 to -$4.302$24M11
Dec 2027-$0.08-$0.73 to $0.572$316M11
Dec 2028$1.58-$0.16 to $3.993--
Dec 2029$6.56$3.78 to $9.342--

Analyst Rating Changes

Are analysts turning bullish or bearish on CELC?

HC Wainwright & Co. most recently reiterated its rating on Celcuity Inc. to Buy on Nov 9, 2026 with a price target of $150 (from $155). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
HC Wainwright & Co.: Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Nov 9, 2026HC Wainwright & Co.MaintainedBuy$155 → $150
Nov 6, 2026GuggenheimMaintainedBuy$171 → $169
Nov 2, 2026GuggenheimMaintainedBuy$175 → $171
Oct 22, 2026Cantor FitzgeraldInitiatedOverweight$140
Oct 21, 2026TD CowenReiteratedBuy$145
Sep 30, 2026NeedhamMaintainedBuy$140 → $134
Sep 17, 2026JP MorganInitiatedOverweight$157
Aug 17, 2026GuggenheimMaintainedBuy$165 → $175
Aug 17, 2026CitizensReiteratedMarket Outperform$177
Aug 14, 2026HC Wainwright & Co.ReiteratedBuy$155
Aug 14, 2026StifelMaintainedBuy$175 → $150
Aug 14, 2026NeedhamMaintainedBuy$157 → $140

Corporate Stakes

Which companies own a stake in CELC?

0.60%held by PFE

Pfizer Inc. reports a stake in Celcuity Inc. on SEC Form 13F: 295.7K shares, about 0.60% of the company, worth $23.5M at the end of Q3 2026. At today's price that stake is worth $19.0M, about 0.01% of PFE's own market value.

Holder
PFE
Shares held
295.7K
Stake
0.60%
Value
$23.5M
HolderLast quarterShares% of CELCValue at filingValue nowChange
Pfizer Inc. PFEUnchanged295.7K0.60%$23.5M$19.0M-19.1%

Form 13F lists US-listed shares held at quarter-end and is filed up to 45 days later. Stakes in private companies are not on it. Value now and Change put those same shares, adjusted for any stock split, at today's price against their reported quarter-end value, so they do not reflect buying or selling since.

Earnings Release, Scored

What did Celcuity Inc.'s latest earnings release say?

Filed Nov 5, 2026 · SEC Form 8-K, Exhibit 99

Tone55.6/ 100-13.5 vs prior release
Hedging words0.17per 100 words-0.11 vs prior release
Tone, last 3 releasesScale 50–81

Most important lines

  1. 1

    Prostate-specific antigen (“PSA”) ≥50% decreases from baseline were observed across all dose levels; response rates were 36%, 47% and 67% at the 120-, 180-, and 240-mg gedatolisib dose levels, respectively, in patients with prior exposure to either abiraterone or enzalutamide.

    New this quarterNegative tone
  2. 2

    The discontinuation rate for gedatolisib due to adverse events was 5% and 4% with the gedatolisib triplet and doublet, respectively, compared to 19% for alpelisib + fulvestrant.

    New this quarterNegative tone
  3. 3

    In the aggregate, $25.3 million of the $27.4 million SG&A increase related to commercial headcount additions and other activities to support the commercialization of REVTORPYK.

ETF holders

ETFs holding CELC

News & sentiment

What is the news saying about CELC?

CELC rose 1.9% over the month to Nov 13. News tone held between 0 and 76 from Oct 14 to Oct 29, then jumped to 75 on Oct 30.

Daily close and news tone, Oct 13 to Nov 13
$60$70Oct 13Oct 14: tone 0Oct 15Oct 16Oct 19Oct 20Oct 21: tone 70Oct 22: tone 76Oct 23: tone 64Oct 26Oct 27Oct 28Oct 29: tone 49Oct 30: tone 75Nov 2Nov 3: tone 52Nov 4Nov 5: tone 71Nov 6: tone 55Nov 9: tone 62Nov 10Nov 11Nov 12Nov 13Oct 13News toneNov 13123
  1. Oct 16 -6.3%
  2. Oct 22 +8.1%same day: Cantor sees ‘credible path to multi-billion-dollar peak sales’ for Celcuity
  3. Nov 5 -7.5%same day: Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Technical analysis

How strong is CELC's momentum right now?

On the daily chart CELC ranks at the 11th percentile for momentum against 1,062 stocks and ETFs, a bearish reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling CELC?

48 of the 70 tracked managers added to CELC in their latest 13F and 21 trimmed. Together they own 32.6% of the company, worth $1.3B. BlackRock and State Street alone hold 10.7%.

48adding21trimming1unchanged
Largest holders by stake, latest 13FBar = share of CELC
  1. $252.7M positionNew position last quarter
  2. $163.5M positionAdded 5.2% last quarter
  3. $154.4M positionAdded 3.6% last quarter
  4. $121.9M positionNew position last quarter
  5. $81.7M positionNew position last quarter
  6. $43.4M positionAdded 6.2% last quarter
  7. $42.9M positionAdded 538.8K shares last quarter
  8. $39.9M positionAdded 1.4% last quarter
  9. $34.1M positionAdded 65.4% last quarter
  10. $35.5M positionAdded 0.3% last quarter
Full holdings history

Discover more

How has CELC done against its peers?

Over the six months to Nov 13, CELC returned −48.9%. Of the 15 related stocks and ETFs, all did better, led by MRNA at +345.8%.

Change since May 13, through Nov 13
−200%0%+200%+400%+600%May 13JulAugSepOctNov 13MRNA +345.8%CELC −48.9%